We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-6.02%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.53B
AUM Growth
-$325M
Cap. Flow
-$296M
Cap. Flow %
-19.34%
Top 10 Hldgs %
65.86%
Holding
300
New
43
Increased
68
Reduced
83
Closed
84

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$95.6M
2
TSRO
TESARO, Inc.
TSRO
+$7.45M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$5.41M
4
MBOT icon
Microbot Medical
MBOT
+$4.73M
5
UTHR icon
United Therapeutics
UTHR
+$4.46M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$6.09M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$5.39M
3
MTFB
Motif Bio plc ADRs
MTFB
+$4.6M
4
OTIC
Otonomy, Inc.
OTIC
+$3.19M
5
PALI icon
Palisade Bio
PALI
+$2.63M

Sector Composition

Rank Sector Weight
1 Healthcare 13%
2 Materials 0.27%
3 Financials 0.11%
4 Consumer Staples 0.03%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EIGR
76
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.76M 0.12%
7,437
-527
-7% -$120K
BNBX
77
DELISTED
BNB PLUS CORP
BNBX
$1.74M 0.11%
2
-1
-33% -$866K
STML
78
DELISTED
Stemline Therapeutics, Inc.
STML
$1.73M 0.11%
187,500
-102,587
-35% -$855K
TRAW icon
79
Traws Pharma
TRAW
$7.31M
$1.69M 0.11%
139
+71
+104% +$882K
SAGE
80
PUT
DELISTED
Sage Therapeutics
SAGE
$1.64M 0.11%
206
-256
-55% -$18.5K
AMAG
81
DELISTED
AMAG Pharmaceuticals
AMAG
$1.64M 0.11%
88,878
+13,615
+18% +$270K
GWPH
82
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$1.57M 0.1%
+15,714
New +$1.69M
SLS icon
83
SELLAS Life Sciences
SLS
$2.01B
$1.54M 0.1%
1,763
+119
+7% +$104K
FLXN
84
CALL
DELISTED
Flexion Therapeutics, Inc.
FLXN
$1.53M 0.1%
755
+239
+46% +$4.98K
HURA
85
TuHURA Biosciences
HURA
$134M
$1.48M 0.1%
+37
New +$1.66M
OTIC
86
CALL
DELISTED
Otonomy, Inc.
OTIC
$1.47M 0.1%
+779
New +$10.9K
EDIT icon
87
Editas Medicine
EDIT
$404M
$1.43M 0.09%
85,000
-5,300
-6% -$95.5K
TSRO
88
CALL
DELISTED
TESARO, Inc.
TSRO
$1.4M 0.09%
100
-102
-50% -$14.8K
FLXN
89
PUT
DELISTED
Flexion Therapeutics, Inc.
FLXN
$1.35M 0.09%
669
+10
+2% +$208
DBVT
90
DBV Technologies
DBVT
$824M
$1.34M 0.09%
+3,750
New +$1.28M
IMMU
91
CALL
DELISTED
Immunomedics Inc
IMMU
$1.32M 0.09%
1,497
– –
ARRY
92
DELISTED
Array Biopharma Inc
ARRY
$1.3M 0.09%
155,757
-317
-0.2% -$2.59K
INCY icon
93
PUT
Incyte
INCY
$25.8B
$1.26M 0.08%
100
-368
-79% -$46.8K
SCPX
94
DELISTED
Scorpius Holdings, Inc.
SCPX
$1.23M 0.08%
7
-2
-22% -$399K
INSM icon
95
CALL
Insmed
INSM
$22.9B
$1.2M 0.08%
701
+38
+6% +$649
ESPR
96
PUT
DELISTED
Esperion Therapeutics
ESPR
$1.19M 0.08%
257
– –
ONCS
97
DELISTED
OncoSec Medical Incorporated
ONCS
$1.15M 0.08%
4,400
-36
-0.8% -$8.83K
STML
98
CALL
DELISTED
Stemline Therapeutics, Inc.
STML
$1.12M 0.07%
1,220
-954
-44% -$7.95K
LUMO
99
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.01M 0.07%
+15,339
New +$1.9M
LUMO
100
PUT
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$995K 0.07%
150
-142
-49% -$17.6K
2 3
4
5 6

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2017 Portfolio in Review

As of Q2 2017, Sabby Management held 300 positions worth $1.53B, down 18% from $1.85B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sabby Management withdrew a net $296M in Q2 2017, closing 84 positions and reducing 83 holdings. Its most notable exit was Amgen, an estimated $6.09M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 6.3% a quarter earlier, followed by Materials and Financials.

Against the trend, Sabby Management opened a new position in TESARO, Inc. worth $7.19M.

  • Sabby Management's largest Q2 2017 buy was TESARO, Inc.: 51,426 shares worth $7.19M.
  • Sabby Management added most to Bristol-Myers Squibb in Q2 2017, an estimated $95.6M increase.
  • Sabby Management's biggest Q2 2017 reduction was Otonomy, Inc., cutting an estimated $3.19M.
  • Sabby Management fully exited Amgen in Q2 2017, selling an estimated $6.09M.
  • Sabby Management's ten largest holdings make up 66% of its $1.53B portfolio in Q2 2017.
  • Sabby Management opened 43 new positions and closed 84 in Q2 2017.
  • Sabby Management's portfolio value fell 18% quarter-over-quarter to $1.53B.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.